Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Xenon (XENE)

Tipranks - Fri Feb 27, 7:32PM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Argenx Se (ARGXResearch Report) and Xenon (XENEResearch Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

Argenx Se (ARGX)

TD Cowen analyst Yaron Werber maintained a Buy rating on Argenx Se yesterday and set a price target of $1146.00. The company’s shares closed last Thursday at $771.53.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 23.6% and a 60.1% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Ionis Pharmaceuticals, and Terns Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $1054.67 average price target, implying a 31.6% upside from current levels. In a report issued on February 19, Jefferies also maintained a Buy rating on the stock with a $1008.00 price target.

See the top stocks recommended by analysts >>

Xenon (XENE)

In a report released today, Myles Minter from William Blair reiterated a Buy rating on Xenon. The company’s shares closed last Thursday at $44.92, close to its 52-week high of $46.00.

According to TipRanks.com, Minter is a 5-star analyst with an average return of 28.2% and a 58.8% success rate. Minter covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Neumora Therapeutics, Inc., and Entrada Therapeutics Inc. ;'>

Currently, the analyst consensus on Xenon is a Strong Buy with an average price target of $55.63, representing a 24.8% upside. In a report issued on February 23, Wolfe Research also initiated coverage with a Buy rating on the stock with a $60.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.